A Proof of Concept Study for GSK2248761 (An Extension of NV-05A-002: A Phase I/IIa Double-Blind Study to Evaluate the Safety and Tolerability, Antiretroviral Activity, Pharmacokinetics and Pharmacodynamics of IDX12899 in Antiretroviral Treatment-Naive HIV-1 Infected Subjects, Completed by Idenix)

Trial Profile

A Proof of Concept Study for GSK2248761 (An Extension of NV-05A-002: A Phase I/IIa Double-Blind Study to Evaluate the Safety and Tolerability, Antiretroviral Activity, Pharmacokinetics and Pharmacodynamics of IDX12899 in Antiretroviral Treatment-Naive HIV-1 Infected Subjects, Completed by Idenix)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Fosdevirine (Primary) ; Antiretrovirals; Lopinavir/ritonavir
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Feb 2012 Results of parent and extension studies published in Antimicrobial Agents and Chemotherapy.
    • 14 Sep 2010 Results of parent study were presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top